Compare
Bioxytran, Inc vs Provectus Biopharmaceuticals, Inc. vs Ocean Biomedical, Inc. vs Bio Essence Corp
| Latest fiscal year | Bioxytran, Inc BIXT | Provectus Biopharmaceuticals, Inc. PVCT | Ocean Biomedical, Inc. OCEALast annual report: year ended 2024-12-31 | Bio Essence Corp BIOE |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 |
| Revenue | n/a | $336.1K | n/a | $1.90M |
| Revenue growth (YoY) | n/a | -45.5% | n/a | +485.8% |
| Gross margin | n/a | n/a | n/a | 75.3% |
| Operating margin | n/a | n/m | n/a | 47.4% |
| Net margin | n/a | n/m | n/a | 47.2% |
| Net income | -$2.12M | -$5.43M | -$9.48M | $896.2K |
| EPS (Diluted) | -$0.02 | -$0.01 | -$0.34 | n/a |
| Operating cash flow | -$526.5K | -$3.33M | -$4.18M | $1.57M |
| Free cash flow | n/a | n/a | n/a | n/a |
| Cash & equivalents | n/a | $251.3K | n/a | n/a |
| Total assets | $658.6K | $697.5K | $902.0K | $422.5K |
| Total liabilities | $3.25M | $7.00M | $98.52M | $2.50M |
| Shareholders' equity | -$2.59M | -$6.30M | -$97.62M | -$2.07M |
| Return on year-end equity | n/a | n/a | n/a | n/a |
| Shares outstanding | 108.15M | 420.28M | 34.87M | 38.01M |
Revenue, most recent five fiscal years
| Fiscal year | Bioxytran, Inc | Provectus Biopharmaceuticals, Inc. | Ocean Biomedical, Inc. | Bio Essence Corp |
|---|---|---|---|---|
| Latest | $191.1K Ended 2017-12-31 | $336.1K Ended 2025-12-31 | n/a | $1.90M Ended 2025-12-31 |
| 1 year earlier | $246.5K Ended 2016-12-31 | $617.1K Ended 2024-12-31 | n/a | $323.9K Ended 2024-12-31 |
| 2 years earlier | $255.8K Ended 2015-12-31 | $557.7K Ended 2023-12-31 | n/a | $551.5K Ended 2023-12-31 |
| 3 years earlier | $275.6K Ended 2014-12-31 | $989.0K Ended 2022-12-31 | n/a | $621.6K Ended 2022-12-31 |
| 4 years earlier | $417.3K Ended 2013-12-31 | n/a | n/a | $888.0K Ended 2021-12-31 |